<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02502110</url>
  </required_header>
  <id_info>
    <org_study_id>ISSCRES0175</org_study_id>
    <nct_id>NCT02502110</nct_id>
  </id_info>
  <brief_title>Study of Statin for Reduction of Postoperative Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will select all recruited patients with paroxysmal atrial fibrillation will be
      randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before
      ablation and last for 3 months. To observe the early relapse of atrial fibrillation and the
      changes of white blood cell count, hs-C reactive protein (CRP), interleukin (IL)-6 and tumor
      necrosis factor (TNF)-α, and the changes of safety indicators .

      This study assumes that the early atrial fibrillation (AF) recurrence will be decreased in
      patients with paroxysmal AF if rosuvastatin 20mg/d is received from 7 days before surgery in
      these patients who plan to undergo radiofrequency catheter ablation for consecutive 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, multi-centers, parallel-control study to explore
      whether rosuvastatin 20mg/d could decrease early AF recurrence in patients with paroxysmal AF
      after radiofrequency catheter ablation. 346 patients with paroxysmal AF are planned to be
      enrolled. The patients are randomized to receive oral rosuvastatin 20mg/d or control therapy
      from 7 days before operation and last for 3 months. The early AF recurrence within 90 days
      after ablation and the changes of 4 inflammatory markers including white blood cell count,
      hs-CRP, IL-6 and TNF-α and safety indicators will be observed. The study is aim to evaluate
      the efficacy and safety of rosuvastatin on decreasing early recurrence in patients with
      paroxysmal AF and discuss its mechanisms of action.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the AF recurrence rate</measure>
    <time_frame>within 90 days after radiofrequency catheter ablation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the AF recurrence rate</measure>
    <time_frame>at 24 hours, 72 hours, 1month, 2 months and 3 months after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory markers (white blood cell count)</measure>
    <time_frame>at 24 hours, 72 hours, and 3 months after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory markers (hs-CRP)</measure>
    <time_frame>at 24 hours, 72 hours, and 3 months after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory markers (IL-6)</measure>
    <time_frame>at 24 hours, 72 hours, and 3 months after operation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The inflammatory markers (TNF-α)</measure>
    <time_frame>at 24 hours, 72 hours, and 3 months after operation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">346</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>rosuvastatin 20mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To receive oral rosuvastatin 20mg/day and regular therapy from 7 days before ablation and last for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>blank control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Regular therapy from 7 days before ablation and last for 3 months. Regular medicines used for AF includes warfarin, metoprolol sustained release tablet, amiodarone, perindopril and irbesartan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rosuvastatin</intervention_name>
    <description>All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.</description>
    <arm_group_label>rosuvastatin 20mg/day</arm_group_label>
    <other_name>crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent prior to any study specific procedures;

          2. Age from 18 to 75 years old, male or female;

          3. The course of paroxysmal AF is more than 3 months and confirmed by ECG;

          4. Plan to undergo radiofrequency catheter ablation

        Exclusion Criteria:

          1. Concomitant with serious organic heart disease such as valvular heart diseases,
             congenital heart diseases, hypertrophic obstructive cardiomyopathy, acute myocardial
             infarction and unstable angina pectoris;

          2. Concomitant with sinoatrial node functional disorder and (or) atrioventricular block;

          3. Acute cerebral apoplexy or contraindication of anticoagulant;

          4. Thyroid function abnormality;

          5. Accepted radiofrequency catheter ablation (RFCA) previously;

          6. Being receiving other statins;

          7. Be allergic to statins;

          8. Pregnancy or women during lactation period;

          9. Be not aligning to treatment or follow-up due to mental disorders or other reasons;

         10. Be with myopathy or active hepatopathy including agnogenic persistent elevation of
             serum transaminase and any serum transaminase being over 3 times of upper limit of
             normal;

         11. Be with serious renal dysfunction (creatinine≥3 mg/dL);

         12. Need steroid or non-steroid anti-inflammatory drugs to treat inflammation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhihui zhang, ViceDirector</last_name>
    <role>Principal Investigator</role>
    <affiliation>Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhihui zhang, ViceDirector</last_name>
    <phone>+86-13687338286</phone>
    <email>zhangzhihui0869@163.com</email>
  </overall_contact>
  <reference>
    <citation>European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429. doi: 10.1093/eurheartj/ehq278. Epub 2010 Aug 29. Erratum in: Eur Heart J. 2011 May;32(9):1172.</citation>
    <PMID>20802247</PMID>
  </reference>
  <reference>
    <citation>Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, Dudley SC Jr. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem. 2007 Sep;53(9):1652-7. Epub 2007 Jun 28.</citation>
    <PMID>17599958</PMID>
  </reference>
  <reference>
    <citation>Anselmi A, Possati G, Gaudino M. Postoperative inflammatory reaction and atrial fibrillation: simple correlation or causation? Ann Thorac Surg. 2009 Jul;88(1):326-33. doi: 10.1016/j.athoracsur.2009.01.031. Review.</citation>
    <PMID>19559266</PMID>
  </reference>
  <reference>
    <citation>Ramlawi B, Otu H, Mieno S, Boodhwani M, Sodha NR, Clements RT, Bianchi C, Sellke FW. Oxidative stress and atrial fibrillation after cardiac surgery: a case-control study. Ann Thorac Surg. 2007 Oct;84(4):1166-72; discussion 1172-3.</citation>
    <PMID>17888965</PMID>
  </reference>
  <reference>
    <citation>Korantzopoulos P, Kolettis T, Siogas K, Goudevenos J. Atrial fibrillation and electrical remodeling: the potential role of inflammation and oxidative stress. Med Sci Monit. 2003 Sep;9(9):RA225-9. Review.</citation>
    <PMID>12960937</PMID>
  </reference>
  <reference>
    <citation>Chimenti C, Russo MA, Carpi A, Frustaci A. Histological substrate of human atrial fibrillation. Biomed Pharmacother. 2010 Mar;64(3):177-83. doi: 10.1016/j.biopha.2009.09.017. Epub 2009 Nov 18. Review.</citation>
    <PMID>20006465</PMID>
  </reference>
  <reference>
    <citation>Kottkamp H, Tanner H, Kobza R, Schirdewahn P, Dorszewski A, Gerds-Li JH, Carbucicchio C, Piorkowski C, Hindricks G. Time courses and quantitative analysis of atrial fibrillation episode number and duration after circular plus linear left atrial lesions: trigger elimination or substrate modification: early or delayed cure? J Am Coll Cardiol. 2004 Aug 18;44(4):869-77.</citation>
    <PMID>15312874</PMID>
  </reference>
  <reference>
    <citation>Lee SH, Tai CT, Hsieh MH, Tsai CF, Lin YK, Tsao HM, Yu WC, Huang JL, Ueng KC, Cheng JJ, Ding YA, Chen SA. Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. J Interv Card Electrophysiol. 2004 Jun;10(3):221-6.</citation>
    <PMID>15133358</PMID>
  </reference>
  <reference>
    <citation>Sawhney N, Anousheh R, Chen W, Feld GK. Circumferential pulmonary vein ablation with additional linear ablation results in an increased incidence of left atrial flutter compared with segmental pulmonary vein isolation as an initial approach to ablation of paroxysmal atrial fibrillation. Circ Arrhythm Electrophysiol. 2010 Jun;3(3):243-8. doi: 10.1161/CIRCEP.109.924878. Epub 2010 Mar 25.</citation>
    <PMID>20339034</PMID>
  </reference>
  <reference>
    <citation>McCabe JM, Smith LM, Tseng ZH, Badhwar N, Lee BK, Lee RJ, Scheinman MM, Olgin JE, Marcus GM. Protracted CRP elevation after atrial fibrillation ablation. Pacing Clin Electrophysiol. 2008 Sep;31(9):1146-51. doi: 10.1111/j.1540-8159.2008.01155.x.</citation>
    <PMID>18834466</PMID>
  </reference>
  <reference>
    <citation>Kothe H, Dalhoff K, Rupp J, Müller A, Kreuzer J, Maass M, Katus HA. Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae. Circulation. 2000 Apr 18;101(15):1760-3.</citation>
    <PMID>10769273</PMID>
  </reference>
  <reference>
    <citation>Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J. 2005 Oct;26(20):2083-92. Epub 2005 Jun 23. Review.</citation>
    <PMID>15975993</PMID>
  </reference>
  <reference>
    <citation>Hayashidani S, Tsutsui H, Shiomi T, Suematsu N, Kinugawa S, Ide T, Wen J, Takeshita A. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002 Feb 19;105(7):868-73.</citation>
    <PMID>11854129</PMID>
  </reference>
  <reference>
    <citation>Young-Xu Y, Jabbour S, Goldberg R, Blatt CM, Graboys T, Bilchik B, Ravid S. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003 Dec 15;92(12):1379-83.</citation>
    <PMID>14675569</PMID>
  </reference>
  <reference>
    <citation>Kourliouros A, Valencia O, Hosseini MT, Mayr M, Sarsam M, Camm J, Jahangiri M. Preoperative high-dose atorvastatin for prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg. 2011 Jan;141(1):244-8. doi: 10.1016/j.jtcvs.2010.06.006. Epub 2010 Jul 10.</citation>
    <PMID>20624624</PMID>
  </reference>
  <reference>
    <citation>Ozaydin M, Varol E, Aslan SM, Kucuktepe Z, Dogan A, Ozturk M, Altinbas A. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol. 2006 May 15;97(10):1490-3. Epub 2006 Mar 29.</citation>
    <PMID>16679090</PMID>
  </reference>
  <reference>
    <citation>Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003 Dec 1;92(11):1343-5.</citation>
    <PMID>14636918</PMID>
  </reference>
  <reference>
    <citation>Almroth H, Höglund N, Boman K, Englund A, Jensen S, Kjellman B, Tornvall P, Rosenqvist M. Atorvastatin and persistent atrial fibrillation following cardioversion: a randomized placebo-controlled multicentre study. Eur Heart J. 2009 Apr;30(7):827-33. doi: 10.1093/eurheartj/ehp006. Epub 2009 Feb 6.</citation>
    <PMID>19202157</PMID>
  </reference>
  <reference>
    <citation>Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation. 2006 Oct 3;114(14):1455-61. Epub 2006 Sep 25.</citation>
    <PMID>17000910</PMID>
  </reference>
  <reference>
    <citation>Maggioni AP, Fabbri G, Lucci D, Marchioli R, Franzosi MG, Latini R, Nicolosi GL, Porcu M, Cosmi F, Stefanelli S, Tognoni G, Tavazzi L; GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur Heart J. 2009 Oct;30(19):2327-36. doi: 10.1093/eurheartj/ehp357. Epub 2009 Aug 30.</citation>
    <PMID>19717850</PMID>
  </reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2015</study_first_posted>
  <last_update_submitted>July 20, 2015</last_update_submitted>
  <last_update_submitted_qc>July 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>statin</keyword>
  <keyword>radiofrequency ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

